Pharmacogenomics: Current state-of-the-art

Genes

Volumn 5, Issue 2, 2014, Pages 430-443

  Carr, Daniel F ^a   Alfirevic, Ana ^a   Pirmohamed, Munir ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Personalized medicine; Pharmacogenetics; Pre treatment genetic testing

Indexed keywords

ALLOPURINOL; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CARBAMAZEPINE; CETUXIMAB; CLOPIDOGREL; CRIZOTINIB; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUCLOXACILLIN; FLUOROURACIL; IMATINIB; PANITUMUMAB; PEGINTERFERON; PERTUZUMAB; PRASUGREL; SIMVASTATIN; TRASTUZUMAB; UNTRANSLATED RNA; VEMURAFENIB; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; BREAST CANCER; COLORECTAL CANCER; DIAGNOSTIC KIT; DRUG EFFICACY; DRUG SAFETY; EPILEPSY; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL STROMAL TUMOR; GENE AMPLIFICATION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; GOUT; HEPATITIS C; HUMAN; HUMAN GENOME PROJECT; HYPERCHOLESTEROLEMIA; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MELANOMA; MULTIPLE MYELOMA; PERSONALIZED MEDICINE; PHARMACOGENOMICS; POINT OF CARE TESTING; PRESCRIPTION; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84902282939     PISSN: None     EISSN: 20734425     Source Type: Journal    
DOI: 10.3390/genes5020430     Document Type: Review

References (57)

1. Lander, E.S.; Linton, L.M.; Birren, B.; Nusbaum, C.; Zody, M.C.; Baldwin, J.; Devon, K.; Dewar, K.; Doyle, M.; FitzHugh, W.; et al. Initial sequencing and analysis of the human genome. Nature 2001, 409, 860-921.
2. Vogel, F. Moderne probleme der humangenetik. Ergeb. Inn. Med. Kinderheilkd 1959, 12, 52-125.
3. Watson, J.D.; Crick, F.H. Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid. Nature 1953, 171, 737-738.
4. International HapMap Consortium. The international hapmap project. Nature 2003, 426, 789-796.
5. Hindorff, L.A.; Sethupathy, P.; Junkins, H.A.; Ramos, E.M.; Mehta, J.P.; Collins, F.S.; Manolio, T.A. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc. Natl. Acad. Sci. USA 2009, 106, 9362-9367.
6. Link, E.; Parish, S.; Armitage, J.; Bowman, L.; Heath, S.; Matsuda, F.; Gut, I.; Lathrop, M.; Collins, R. Slco1b1 variants and statin-induced myopathy-A genomewide study. New Engl. J. Med. 2008, 359, 789-799.
7. Sarasquete, M.E.; Garcia-Sanz, R.; Marin, L.; Alcoceba, M.; Chillon, M.C.; Balanzategui, A.; Santamaria, C.; Rosinol, L.; de la Rubia, J.; Hernandez, M.T.; et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome p450 cyp2c8 in multiple myeloma: A genome-wide single nucleotide polymorphism analysis. Blood 2008, 112, 2709-2712.
8. Kindmark, A.; Jawaid, A.; Harbron, C.G.; Barratt, B.J.; Bengtsson, O.F.; Andersson, T.B.; Carlsson, S.; Cederbrant, K.E.; Gibson, N.J.; Armstrong, M.; et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 2008, 8, 186-195.
9. Daly, A.K.; Donaldson, P.T.; Bhatnagar, P.; Shen, Y.; Pe'er, I.; Floratos, A.; Daly, M.J.; Goldstein, D.B.; John, S.; Nelson, M.R.;. Hla-b*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet. 2009, 41, 816-819.
10. McCormack, M.; Alfirevic, A.; Bourgeois, S.; Farrell, J.J.; Kasperaviciute, D.; Carrington, M.; Sills, G.J.; Marson, T.; Jia, X.; de Bakker, P.I.; et al. Hla-a*3101 and carbamazepine-induced hypersensitivity reactions in europeans. New Engl. J. Med. 2011, 364, 1134-1143.
11. Ozeki, T.; Mushiroda, T.; Yowang, A.; Takahashi, A.; Kubo, M.; Shirakata, Y.; Ikezawa, Z.; Iijima, M.; Shiohara, T.; Hashimoto, K.; et al. Genome-wide association study identifies hla-a*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in japanese population. Hum. Mol. Gen. 2011, 20, 1034-1041.
12. Tohkin, M.; Kaniwa, N.; Saito, Y.; Sugiyama, E.; Kurose, K.; Nishikawa, J.; Hasegawa, R.; Aihara, M.; Matsunaga, K.;Abe, M.; et al. A whole-genome association study of major determinants for allopurinol-related stevens-johnson syndrome and toxic epidermal necrolysis in japanese patients. Pharmacogenomics J. 2013, 13, 60-69.
13. Shuldiner, A.R.; O'Connell, J.R.; Bliden, K.P.; Gandhi, A.; Ryan, K.; Horenstein, R.B.; Damcott, C.M.; Pakyz, R.; Tantry, U.S.; Gibson Q.; et al. Association of cytochrome p450 2c19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009, 302, 849-857.
14. Ge, D.; Fellay, J.; Thompson, A.J.; Simon, J.S.; Shianna, K.V.; Urban, T.J.; Heinzen, E.L.; Qiu, P.; Bertelsen, A.H.; Muir, A.J.; et al. Genetic variation in il28b predicts hepatitis c treatment-induced viral clearance. Nature 2009, 461, 399-401.
15. Takeuchi, F.; McGinnis, R.; Bourgeois, S.; Barnes, C.; Eriksson, N.; Soranzo, N.; Whittaker, P.; Ranganath, V.; Kumanduri, V.; McLaren, W.; et al. A genome-wide association study confirms vkorc1, cyp2c9, and cyp4f2 as principal genetic determinants of warfarin dose. PLoS Genet. 2009, 5, e1000433.
16. The 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. Nature 2010, 467, 1061-1073.
17. Gordon, A.S.; Tabor, H.K.; Johnson, A.D.; Snively, B.M.; Assimes, T.L.; Auer, P.L.; Ioannidis, J.P.; Peters, U.; Robinson, J.G.; Sucheston, L.E.; et al. Quantifying rare, deleterious variation in 12 human cytochrome p450 drug-metabolism genes in a large-scale exome dataset. Hum. Mol. Gen. 2014. 23, 1957-1963.
18. Wadelius, M.; Chen, L.Y.; Lindh, J.D.; Eriksson, N.; Ghori, M.J.; Bumpstead, S.; Holm, L.; McGinnis, R.; Rane, A.; Deloukas, P. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009, 113, 784-792.
19. Ainle, F.N.; Mumford, A.; Tallon, E.; McCarthy, D.; Murphy, K. A vitamin k epoxide reductase complex subunit 1 mutation in an irish patient with warfarin resistance. Irish J. Med. Sci. 2008, 177, 159-161.
20. Harrington, D.J.; Gorska, R.; Wheeler, R.; Davidson, S.; Murden, S.; Morse, C.; Shearer, M.J.; Mumford, A.D. Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in vkorc1. J. Thrombosis Haemost. 2008, 6, 1663-1670.
21. Harrington, D.J.; Underwood, S.; Morse, C.; Shearer, M.J.; Tuddenham, E.G.; Mumford, A.D. Pharmacodynamic resistance to warfarin associated with a val66met substitution in vitamin k epoxide reductase complex subunit 1. Thromb. Haemost. 2005, 93, 23-26.
22. Rost, S.; Fregin, A.; Ivaskevicius, V.; Conzelmann, E.; Hortnagel, K.; Pelz, H.J.; Lappegard, K.; Seifried, E.; Scharrer, I.; Tuddenham, E.G.; Mutations in vkorc1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004, 427, 537-541.
23. Behr, E.R.; Roden, D. Drug-induced arrhythmia: Pharmacogenomic prescribing? Eur. Heart J. 2013, 34, 89-95.
24. Ramirez, A.H.; Shaffer, C.M.; Delaney, J.T.; Sexton, D.P.; Levy, S.E.; Rieder, M.J.; Nickerson, D.A.; George, A.L., Jr.; Roden, D.M. Novel rare variants in congenital cardiac arrhythmia genes are frequent in drug-induced torsades de pointes. Pharmacogenomics J. 2013, 13, 325-329.
25. Consortium, E.P.; Bernstein, B.E.; Birney, E.; Dunham, I.; Green, E.D.; Gunter, C.; Snyder, M. An integrated encyclopedia of DNA elements in the human genome. Nature 2012, 489, 57-74.
26. Starkey Lewis, P.J.; Dear, J.; Platt, V.; Simpson, K.J.; Craig, D.G.; Antoine, D.J.; French, N.S.; Dhaun, N.; Webb, D.J.; Costello, E.M.; et al. Circulating micrornas as potential markers of human drug-induced liver injury. Hepatology 2011, 54, 1767-1776.
27. Ichihara, A.; Wang, Z.; Jinnin, M.; Izuno, Y.; Shimozono, N.; Yamane, K.; Fujisawa, A.; Moriya, C.; Fukushima, S.; Inoue, Y.; et al. Upregulation of mir-18a-5p contributes to epidermal necrolysis in severe drug eruptions. J. Allergy Clin. Immunol. 2013, 133, 1065-1074.
28. Poste, G. Bring on the biomarkers. Nature 2011, 469, 156-157.
29. US Food and Drug Administration. Table of Pharmacogenomic Biomarkers in Drug Labeling. Available online: http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ ucm083378.htm/ (6 November 2013).
30. Relling, M.V.; Klein, T.E. Cpic: Clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin. Pharmacol. Ther. 2011, 89, 464-467.
31. Pirmohamed, M.; Friedmann, P.S.; Molokhia, M.; Loke, Y.K.; Smith, C.; Phillips, E.; La Grenade, L.; Carleton, B.; Papaluca-Amati, M.; Demoly, P.; et al. Phenotype standardization for immune-mediated drug-induced skin injury. Clin. Pharmacol. Ther. 2011, 89, 896-901.
32. Pirmohamed, M.; Aithal, G.P.; Behr, E.; Daly, A.; Roden, D. The phenotype standardization project: Improving pharmacogenetic studies of serious adverse drug reactions. Clin. Pharmacol. Ther. 2011, 89, 784-785.
33. Behr, E.R.; January, C.; Schulze-Bahr, E.; Grace, A.A.; Kaab, S.; Fiszman, M.; Gathers, S.; Buckman, S.; Youssef, A.; Pirmohamed, M.;. The international serious adverse events consortium (isaec) phenotype standardization project for drug-induced torsades de pointes. Eur. Heart J. 2012. 34, 1958-1963
34. Saiki, R.K.; Gelfand, D.H.; Stoffel, S.; Scharf, S.J.; Higuchi, R.; Horn, G.T.; Mullis, K.B.; Erlich, H.A. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988, 239, 487-491.
35. Pirmohamed, M.; Burnside, G.; Eriksson, N.; Jorgensen, A.L.; Toh, C.H.; Nicholson, T.; Kesteven, P.; Christersson, C.; Wahlstrom, B.; Stafberg, C.; et al. A randomized trial of genotype-guided dosing of warfarin. New Engl. J. Med. 2013, 369, 2294-2303.
36. Roberts, J.D.; Wells, G.A.; Le May, M.R.; Labinaz, M.; Glover, C.; Froeschl, M.; Dick, A.; Marquis, J.F.; O'Brien, E.; Goncalves, S.; et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (rapid gene): A prospective, randomised, proof-of-concept trial. Lancet 2012, 379, 1705-1711.
37. Lezhava, A.; Ishidao, T.; Ishizu, Y.; Naito, K.; Hanami, T.; Katayama, A.; Kogo, Y.; Soma, T.; Ikeda, S.; Murakami, K.; et al. Exciton primer-mediated snp detection in smartamp2 reactions. Hum. Mut. 2010, 31, 208-217.
38. Aomori, T.; Yamamoto, K.; Oguchi-Katayama, A.; Kawai, Y.; Ishidao, T.; Mitani, Y.; Kogo, Y.; Lezhava, A.; Fujita, Y.; Obayashi, K.; et al. Rapid single-nucleotide polymorphism detection of cytochrome p450 (cyp2c9) and vitamin k epoxide reductase (vkorc1) genes for the warfarin dose adjustment by the smart-amplification process version 2. Clin. Chem. 2009, 55, 804-812.
39. Burn, J. Company profile: Quantumdx group limited. Pharmacogenomics 2013, 14, 1011-1015.
40. Stedtfeld, R.D.; Tourlousse, D.M.; Seyrig, G.; Stedtfeld, T.M.; Kronlein, M.; Price, S.; Ahmad, F.; Gulari, E.; Tiedje, J.M.; Hashsham, S.A. Gene-z: A device for point of care genetic testing using a smartphone. Lab. Chip 2012, 12, 1454-1462.
41. Realising the potential of stratified medicine; Academy of Medical Sciences: London, UK, 2013.
42. Yamamoto, N.; Murakami, H.; Hayashi, H.; Fujisaka, Y.; Hirashima, T.; Takeda, K.; Satouchi, M.; Miyoshi, K.; Akinaga, S.; Takahashi, T.; et al. Cyp2c19 genotype-based phase i studies of a c-met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer. Br. J. Cancer 2013, 109, 2803-2809.
43. European Medicines Agency. Guideline on the Use of Pharmacogenetic Methodologies in the Pharmacokinetic Evaluation of Medicinal Products. Available online: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/02/WC500121954.pdf (accessed on 30 October 2012).
44. Pulley, J.M.; Denny, J.C.; Peterson, J.F.; Bernard, G.R.; Vnencak-Jones, C.L.; Ramirez, A.H.; Delaney, J.T.; Bowton, E.; Brothers, K.; Johnson, K.; et al. Operational implementation of prospective genotyping for personalized medicine: The design of the vanderbilt predict project. Clin. Pharmacol. Ther. 2012, 92, 87-95.
45. Pirmohamed, M. Pharmacogenetics: Past, present and future. Drug Discov. Today 2011, 16, 852-861.
46. Moore, G.E. Cramming more components onto integrated circuits. Electronics 1965, 38, 114-117.
47. Ross, J.S.; Slodkowska, E.A.; Symmans, W.F.; Pusztai, L.; Ravdin, P.M.; Hortobagyi, G.N. The her-2 receptor and breast cancer: Ten years of targeted anti-her-2 therapy and personalized medicine. Oncologist 2009, 14, 320-368.
48. Goldstein, N.S.; Armin, M. Epidermal growth factor receptor immunohistochemical reactivity in patients with american joint committee on cancer stage iv colon adenocarcinoma: Implications for a standardized scoring system. Cancer 2001, 92, 1331-1346.
49. Went, P.T.; Dirnhofer, S.; Bundi, M.; Mirlacher, M.; Schraml, P.; Mangialaio, S.; Dimitrijevic, S.; Kononen, J.; Lugli, A.; Simon, R.; et al. Prevalence of kit expression in human tumors. J. Clin. Oncol. 2004, 22, 4514-4522.
50. Martelli, M.P.; Sozzi, G.; Hernandez, L.; Pettirossi, V.; Navarro, A.; Conte, D.; Gasparini, P.; Perrone, F.; Modena, P.; Pastorino, U.; et al. Eml4-alk rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am. J. Pathol. 2009, 174, 661-670.
51. Greaves, W.O.; Verma, S.; Patel, K.P.; Davies, M.A.; Barkoh, B.A.; Galbincea, J.M.; Yao, H.; Lazar, A.; Aldape, K.D.; Medeiros, L.J., et al. Frequency and spectrum of braf mutations in a retrospective, single-institution study of 1112 cases of melanoma. J. Mol. Diagn. 2012, 15, 220-226.
52. Brink, M.; de Goeij, A.F.; Weijenberg, M.P.; Roemen, G.M.; Lentjes, M.H.; Pachen, M.M.; Smits, K.M.; de Bruine, A.P.; Goldbohm, R.A.; van den Brandt, P.A. K-ras oncogene mutations in sporadic colorectal cancer in the netherlands cohort study. Carcinogenesis 2003, 24, 703-710.
53. Dorschner, M.O.; Amendola, L.M.; Turner, E.H.; Robertson, P.D.; Shirts, B.H.; Gallego, C.J.; Bennett, R.L.; Jones, K.L.; Tokita, M.J.; Bennett, J.T., et al. Actionable, pathogenic incidental findings in 1,000 participants' exomes. Am. J. Hum. Genet. 2013, 93, 631-640.
54. Green, R.C.; Berg, J.S.; Grody, W.W.; Kalia, S.S.; Korf, B.R.; Martin, C.L.; McGuire, A.L.; Nussbaum, R.L.; O'Daniel, J.M.; Ormond, K.E., et al. Acmg recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet. Med. 2013, 15, 565-574.
55. Kocarnik, J.M.; Fullerton, S.M. Returning pleiotropic results from genetic testing to patients and research participants. JAMA 2014, 311, 795-796.
56. Patel, H.N.; Ursan, I.D.; Zueger, P.M.; Cavallari, L.H.; Pickard, A.S. Stakeholder views on pharmacogenomic testing. Pharmacotherapy 2014, 34, 151-165.
57. Senderowicz, A.M.; Pfaff, O. Similarities and differences in the oncology drug approval process between fda and european union with emphasis on in vitro companion diagnostics. Clin. Cancer Res. 2014, 20, 1445-1452.